Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy : differences according to KRAS G12C vs. non-G12C
Notario, Lucía (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Cucurull, Marc (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Cerdà, Gabriela (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Sanz, Carolina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Carcereny, Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Muñoz-Mármol, Ana (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Hernández, Ainhoa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Domènech, Marta (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Sanchez-Cespedes, Montse (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Costa, Marta (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Mate, Jose Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Esteve, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Saigí, Maria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Date: |
2023 |
Abstract: |
Approximately 20% of lung adenocarcinomas harbor activating mutations at KRAS, an oncogene with the ability to alter the tumor immune microenvironment. In this retrospective study, we examined 103 patients with KRAS-mutant lung adenocarcinoma who were treated with immunotherapy-based regimens and we evaluated the clinical outcomes according to PD-L1 expression and the type of KRAS mutation. Among all patients included, 47% carried KRAS G12C mutation whereas 53% harbored KRAS non-G12C mutations. PD-L1 status was available for 77% of cases, with higher expression among KRAS G12C tumors (p = 0. 01). Better overall survival and progression-free survival were observed in high PD-L1 expression tumors, regardless of KRAS mutation type. The heterogeneous nature of KRAS-mutant tumors and the presence of other co-mutations may contribute to different outcomes to immunotherapy-based strategies. |
Grants: |
Instituto de Salud Carlos III CM19/0068 Instituto de Salud Carlos III JR20/00015
|
Rights: |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. |
Language: |
Anglès |
Document: |
Article ; recerca ; Versió publicada |
Subject: |
Non-small cell lung cancer ;
Lung adenocarcinoma ;
KRAS ;
PD-L1 ;
Immunotherapy |
Published in: |
Frontiers in Oncology, Vol. 13 (october 2023) , ISSN 2234-943X |
DOI: 10.3389/fonc.2023.1239000
PMID: 37916173
The record appears in these collections:
Research literature >
UAB research groups literature >
Research Centres and Groups (research output) >
Health sciences and biosciences >
Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP) >
Josep Carreras Leukaemia Research Institute Articles >
Research articlesArticles >
Published articles
Record created 2024-03-01, last modified 2024-05-04